The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Novel KRAS-targeting agents on the horizon
Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, talks on new KRAS-targeting agents on the horizon including G12C inhibitors, pan-RAS inhibitors and exon 12 targeting agents. Mechanisms of adaptive resistance currently under investigation will likely be relative to all forms of KRAS inhibitors. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
